Tangible Shareholders Equity: The value shareholders equity less intangible assets.
Crescent Biopharma, Inc. (CBIO) had Tangible Shareholders Equity of $116.64M for the most recently reported fiscal quarter, ending 2025-09-30.
| Income Statement Financials | |
-- |
|
$-24.61M |
|
-- |
|
-- |
|
$25.89M |
|
$-25.89M |
|
$1.28M |
|
$-24.61M |
|
$-24.61M |
|
$-24.61M |
|
$-24.61M |
|
$-24.61M |
|
$-24.61M |
|
$-25.89M |
|
$-25.86M |
|
16.54M |
|
16.54M |
|
$-1.27 |
|
$-1.27 |
|
| Balance Sheet Financials | |
$134.56M |
|
$0.78M |
|
$3.71M |
|
$138.27M |
|
$20.30M |
|
-- |
|
$1.32M |
|
$21.63M |
|
$112.64M |
|
|
Tangible Shareholders Equity |
$116.64M |
$116.64M |
|
13.89M |
|
| Cash Flow Statement Financials | |
$-44.79M |
|
$-0.73M |
|
$144.12M |
|
$34.77M |
|
$133.37M |
|
$98.61M |
|
$8.55M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
6.63 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-45.52M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-21.85% |
|
-21.10% |
|
-17.80% |
|
-21.10% |
|
$8.40 |
|
$-2.75 |
|
$-2.71 |
|